gefitinib

You have access
Gefitinib Enhances Mitochondrial Biological Functions in NSCLCs with EGFR Mutations at a High Cell Density
TOMOYA TAKENAKA, MIKU KATAYAMA, AYAKA SUGIYAMA, MASAYA HAGIWARA, IKUO FUJII, TOMOKA TAKATANI-NAKASE, SUSUMU S. KOBAYASHI and IKUHIKO NAKASE

Anticancer Research September 2017, 37 (9) 4779-4788;
You have access
Impact of Small Molecules on β-Catenin and E-Cadherin Expression in HPV16-positive and -negative Squamous Cell Carcinomas
BENEDIKT KRAMER, CLEMENS HOCK, JOHANNES DAVID SCHULTZ, ANNE LAMMERT, BEATRICE KUHLIN, RICHARD BIRK, KARL HÖRMANN and CHRISTOPH ADERHOLD

Anticancer Research June 2017, 37 (6) 2845-2852;
You have access
Targeted Therapies in HPV-positive and -negative HNSCC – Alteration of EGFR and VEGFR-2 Expression In Vitro
BENEDIKT KRAMER, CLEMENS HOCK, RICHARD BIRK, ALEXANDER SAUTER, BORIS A. STUCK, KARL HÖRMANN, JOHANNES DAVID SCHULTZ and CHRISTOPH ADERHOLD

Anticancer Research June 2016, 36 (6) 2799-2807;
You have access
Comparison of Gefitinib Versus Chemotherapy in Patients with Non-small Cell Lung Cancer with Exon 19 Deletion
SATOSHI WATANABE, AKIRA INOUE, TOSHIHIRO NUKIWA and KUNIHIKO KOBAYASHI

Anticancer Research December 2015, 35 (12) 6957-6961;
You have access
MMP9, Cyclin D1 and β-Catenin Are Useful Markers of p16-positive Squamous Cell Carcinoma in Therapeutic EGFR Inhibition In Vitro
CLAUDIA UMBREIT, PHILIPP ERBEN, ANNE FABER, RALF-DIETER HOFHEINZ, CHRISTOPH ADERHOLD, CHRISTEL WEISS, KARL HOERMANN, ANGELA WENZEL and JOHANNES DAVID SCHULTZ

Anticancer Research July 2015, 35 (7) 3801-3810;
You have access
Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212)
TOMOYUKI OTSUKA, MASAHIDE MORI, YUKIHIRO YANO, JUNJI UCHIDA, KAZUMI NISHINO, REIKO KAJI, AKITO HATA, YOSHIHIRO HATTORI, YOSHIKO URATA, TOSHIHIKO KANEDA, MOTOKO TACHIHARA, FUMIO IMAMURA, NOBUYUKI KATAKAMI, SHUNICHI NEGORO, SATOSHI MORITA and SOICHIRO YOKOTA

Anticancer Research July 2015, 35 (7) 3885-3891;
You have access
Gefitinib Inhibits Sodium Phosphate Co-transporter III Isoform 1 in a Model of Human Malignant Glioma
CLEMENTINE PUECH, NATHALIE PREVOT and NATHALIE PEREK

Anticancer Research November 2014, 34 (11) 6527-6535;
You have access
Erlotinib Is a Well-tolerated Alternate Treatment for Non-small Cell Lung Cancer in Cases of Gefitinib-induced Hepatotoxicity
KIMIO YONESAKA, TOMOHIRO SUZUMURA, HIROSHI TSUKUDA, YOSHIKAZU HASEGAWA, TOMOHIRO OZAKI, TAKAMUNE SUGIURA and MASAHIRO FUKUOKA

Anticancer Research September 2014, 34 (9) 5211-5215;
You have access
Gefitinib and Afatinib Treatment in an Advanced Non-small Cell Lung Cancer (NSCLC) Patient Undergoing Hemodialysis
MELISSA BERSANELLI, MARCELLO TISEO, FABRIZIO ARTIOLI, LEONARDO LUCCHI and ANDREA ARDIZZONI

Anticancer Research June 2014, 34 (6) 3185-3188;
You have access
Phase II Study of Erlotinib for Acquired Resistance to Gefitinib in Patients with Advanced Non-small Cell Lung Cancer
ATSUSHI HORIIKE, NOBUYUKI YAMAMOTO, HISASHI TANAKA, NORIKO YANAGITANI, KEITA KUDO, FUMIYOSHI OHYANAGI, AKIRA ONO, TATEAKI NAITO, HARUYASU MURAKAMI, TAKESHI HORAI and MAKOTO NISHIO

Anticancer Research April 2014, 34 (4) 1975-1981;

Main menu

User menu

Search

gefitinib

Pages